The global breast reconstruction market size is expected to reach USD 3.15 billion by 2030, registering a CAGR of 6.54% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness significant growth due to the high incidence of breast cancer, increasing volume of reconstructive surgeries, and rising awareness regarding the availability of breast reconstruction procedures. Breast cancer is the most prevalent cancer worldwide. As per the International Agency for Research on Cancer in 2022, about 2,261,419 new breast cancer cases were recorded globally with 9,958,133 deaths in the same year; the same source stated that the number is expected to increase to 7,790,717 by 2025. Thus, with a rise in the number of breast cancer patients, the industry is expected to grow over the coming years.
New product launches, geographic expansions, partnerships, and various strategic initiatives undertaken by major players also support industry growth. Some of the key players, headquartered in the U.S., include Allergan (now part of AbbVie); Mentor (a subsidiary of Johnson & Johnson); Sientra, Establishment Labs S.A.; and Ideal Implant Inc. Due to the presence of leading players in this country, the market is highly competitive. Companies are undertaking various initiatives to strengthen their industry presence. For instance, in June 2023, Sientra, Inc. received FDA approval for its AlloX2 Pro Tissue Expander. Increasing adoption of breast reconstruction surgeries, combined with a growing awareness among women regarding these procedures for aesthetic enhancement, represents a significant catalyst for the market. Women predominantly opt for this surgery to augment breast size and reconstruct breasts following mastectomy, which is expected to fuel industry growth over the forecast period.
Gather more insights about the market drivers, restrains and growth of the Global Breast Reconstruction Market
Breast Reconstruction Market Report Highlights
In terms of product, the implant segment accounted for a revenue share of 60.39% in 2023. The tissue expander segment is anticipated to register the fastest CAGR from 2024 to 2030 due to the rising use of breast implants during breast augmentation surgeriesBased on shape, the round segment dominated the market in 2023 and the anatomical shape segment is anticipated to register the fastest CAGR of 6.67% from 2024 to 2030The anatomical shape of breast implants provides a natural shape and textured surface, therefore, the implant does not shift after placement. Moreover, their texture makes them ideal for breast augmentation in women with little natural breast tissueThe hospitals end-use segment led the industry with a revenue share of 46.79% in 2023. However, the ASCs segment is projected to register the fastest CAGR from 2024 to 2030 owing to the rising number of reconstruction surgeries in ASCsNorth America led the industry with a share of 58.09% in 2023. Asia Pacific is projected to witness the fastest CAGR from 2024 to 2030 owing to rising cases of breast cancer and increasing awareness regarding the availability of breast reconstruction procedures in this regionList of Key Players in Breast Reconstruction Market
Mentor Medical Systems B.V. (Johnson & Johnson)Allergan, Inc. (AbbVie)Sientra, Inc.Ideal Implant IncorporatedEstablishment LabsPOLYTECH Health & Aesthetics GmbHRTI SurgicalSebbinIntegra LifeSciencesGC AestheticsOrder a free sample PDF of the Breast Reconstruction Market Intelligence Study, published by Grand View Research.
